{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:34:30Z","timestamp":1778038470338,"version":"3.51.4"},"reference-count":54,"publisher":"Elsevier","isbn-type":[{"value":"9780443222429","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["K22-043"],"award-info":[{"award-number":["K22-043"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["12553"],"award-info":[{"award-number":["12553"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031220","name":"Laboratoire d'Excellence MAbImprove","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EL 2024"],"award-info":[{"award-number":["EL 2024"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.mcb.2024.05.013","type":"book-chapter","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:06:28Z","timestamp":1718611588000},"page":"131-157","source":"Crossref","is-referenced-by-count":1,"title":["Development of an in vivo ovarian cancer peritoneal carcinomatosis model for radioimmunotherapy testing"],"prefix":"10.1016","member":"78","reference":[{"issue":"9","key":"10.1016\/bs.mcb.2024.05.013_bb0010","first-page":"2806","article-title":"A phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I\/II study","volume":"65","author":"Alvarez","year":"1997","journal-title":"Gynecologic Oncology"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0020","unstructured":"American Cancer Society. Ovarian cancer statistics | How common is ovarian cancer. (n.d.). Retrieved June 1, 2022, from https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html."},{"issue":"1A","key":"10.1016\/bs.mcb.2024.05.013_bb0025","first-page":"409","article-title":"Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer","volume":"21","author":"Andersson","year":"2001","journal-title":"Anticancer Research"},{"issue":"17","key":"10.1016\/bs.mcb.2024.05.013_bb0030","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.2004.09.016","article-title":"Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer","volume":"22","author":"Berek","year":"2004","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.mcb.2024.05.013_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2008.17.8400","article-title":"Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer","volume":"27","author":"Berek","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/bs.mcb.2024.05.013_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069613","article-title":"Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb","volume":"8","author":"Boudousq","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.mcb.2024.05.013_bb0045","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.110.080226","article-title":"Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125 I-labeled monoclonal antibodies","volume":"51","author":"Boudousq","year":"2010","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0050","series-title":"Methods in cell biology","article-title":"Clonogenic assay to measure bystander cytotoxicity of targeted alpha-particle therapy","author":"Constanzo","year":"2022"},{"issue":"8","key":"10.1016\/bs.mcb.2024.05.013_bb0055","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.208611","article-title":"Radiolabeled antibodies against M\u00fcllerian-inhibiting substance receptor, type II: New tools for a theranostic approach in ovarian cancer","volume":"59","author":"Deshayes","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0060","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1200\/JCO.1987.5.12.1890","article-title":"Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered monoclonal antibodies","volume":"5","author":"Epenetos","year":"1988","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"23","key":"10.1016\/bs.mcb.2024.05.013_bb0065","doi-asserted-by":"crossref","first-page":"37061","DOI":"10.18632\/oncotarget.15715","article-title":"The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells","volume":"8","author":"Estupina","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/bs.mcb.2024.05.013_bb0070","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/1097-0142(19950415)75:8<2147::AID-CNCR2820750818>3.0.CO;2-8","article-title":"Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy","volume":"75","author":"Felip","year":"1995","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/bs.mcb.2024.05.013_bb0075","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/ijc.26321","article-title":"L1-CAM-targeted antibody therapy and (177)Lu-radioimmunotherapy of disseminated ovarian cancer","volume":"130","author":"Fischer","year":"2012","journal-title":"International Journal of Cancer"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0080","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.trecan.2022.01.010","article-title":"Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents","volume":"8","author":"Fucikova","year":"2022","journal-title":"Trends in Cancer"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0360-3016(92)90778-G","article-title":"Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma","volume":"22","author":"Fyles","year":"1992","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"12","key":"10.1016\/bs.mcb.2024.05.013_bb0090","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2967\/jnumed.123.265418","article-title":"Gadolinium-based nanoparticles sensitize ovarian peritoneal carcinomatosis to targeted radionuclide therapy","volume":"64","author":"Garcia-Prada","year":"2023","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"issue":"10","key":"10.1016\/bs.mcb.2024.05.013_bb0095","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"8","key":"10.1016\/bs.mcb.2024.05.013_bb0100","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","article-title":"Rational combinations of immunotherapy with radiotherapy in ovarian cancer","volume":"20","author":"Herrera","year":"2019","journal-title":"The Lancet. Oncology"},{"issue":"7","key":"10.1016\/bs.mcb.2024.05.013_bb0105","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/pharmaceutics13070980","article-title":"Targeted radionuclide therapy using auger electron emitters: The quest for the right vector and the right radionuclide","volume":"13","author":"Idrissou","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/bs.mcb.2024.05.013_bb0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86829","article-title":"Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition","volume":"1","author":"Iwanicki","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub3","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"11","author":"Jaaback","year":"2011","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0120","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/ijgc-00009577-200309000-00006","article-title":"Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: Effect of the radionuclide","volume":"13","author":"Janssen","year":"2003","journal-title":"International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society"},{"issue":"2","key":"10.1016\/bs.mcb.2024.05.013_bb0125","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-06-1486","article-title":"Copper-67 radioimmunotherapy and growth inhibition by anti\u2013L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis","volume":"13","author":"Knogler","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Current Opinion in Obstetrics & Gynecology"},{"issue":"15","key":"10.1016\/bs.mcb.2024.05.013_bb0135","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1158\/1078-0432.CCR-18-3295","article-title":"Drugs that modify cholesterol metabolism alter the p38\/JNK-mediated targeted and nontargeted response to alpha and auger radioimmunotherapy","volume":"25","author":"Ladjohounlou","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10.1016\/bs.mcb.2024.05.013_bb0140","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0145","author":"Ludwig Institute for Cancer Research"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191972","article-title":"The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies","volume":"13","author":"Luo","year":"2018","journal-title":"PLoS One"},{"issue":"10 Suppl","key":"10.1016\/bs.mcb.2024.05.013_bb0155","first-page":"3249s","article-title":"A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma","volume":"5","author":"Mah\u00e9","year":"1999","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"9","key":"10.1016\/bs.mcb.2024.05.013_bb0160","first-page":"1491","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49","volume":"37","author":"Meredith","year":"1996","journal-title":"Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine"},{"issue":"10","key":"10.1016\/bs.mcb.2024.05.013_bb0165","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.neo.2015.10.003","article-title":"Specific TP53 mutants overrepresented in ovarian cancer impact CNV, TP53 activity, responses to Nutlin-3a, and cell survival","volume":"17","author":"Mullany","year":"2015","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"12","key":"10.1016\/bs.mcb.2024.05.013_bb0170","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2967\/jnumed.112.107540","article-title":"A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for \u03b1- and \u03b2-radionuclide therapy: An in vivo proof-of-concept study with a new receptor-targeted folate derivative","volume":"53","author":"M\u00fcller","year":"2012","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth879","article-title":"FuGENE\u00ae 6 transfection reagent: Minimizing reagent-dependent side effects as analyzed by gene-expression profiling and cytotoxicity assays","volume":"3","author":"Nagy","year":"2006","journal-title":"Nature Methods"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0180","first-page":"223","article-title":"Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis","volume":"5","author":"Nicholson","year":"1998","journal-title":"Oncology Reports"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0185","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","article-title":"[177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts","volume":"67","author":"Persson","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0190","article-title":"The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2\/M cell cycle arrest","author":"Pichard","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2023.07.014","article-title":"Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors","author":"Pouget","year":"2023","journal-title":"Trends in Cancer"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Frontiers in Medicine"},{"key":"10.1016\/bs.mcb.2024.05.013_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fmed.2015.00012","article-title":"Introduction to radiobiology of targeted radionuclide therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Frontiers in Medicine"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0210","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph5010001","article-title":"Pre-clinical assessment of 177Lu-labeled trastuzumab targeting HER2 for treatment and management of cancer patients with disseminated intraperitoneal disease","volume":"5","author":"Ray","year":"2011","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0220","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/COC.2008.n.005","article-title":"HER2 overexpression\/amplification and Trastuzumab treatment in advanced ovarian cancer: A GINECO phase II study","volume":"1","author":"Ray-Coquard","year":"2008","journal-title":"Clinical Ovarian Cancer"},{"issue":"22","key":"10.1016\/bs.mcb.2024.05.013_bb0225","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.7150\/thno.35461","article-title":"Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: Probe selection and first proof-of-concept","volume":"9","author":"Rondon","year":"2019","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0230","first-page":"953","article-title":"Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effect of dose and EDTA coadministration on pharmacokinetics and toxicity","volume":"5","author":"Rosenblum","year":"1999","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/bs.mcb.2024.05.013_bb0235","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: A critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/gyno.1993.1247","article-title":"Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer","volume":"51","author":"Rubin","year":"1993","journal-title":"Gynecologic Oncology"},{"issue":"12","key":"10.1016\/bs.mcb.2024.05.013_bb0245","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2967\/jnumed.109.066993","article-title":"Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis","volume":"50","author":"Santoro","year":"2009","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"10.1016\/bs.mcb.2024.05.013_bb0250","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0360-3016(03)00408-5","article-title":"Beta dose-rate distributions in microscopic spherical tumors for intraperitoneal radioimmunotherapy","volume":"56","author":"Syme","year":"2003","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"3","key":"10.1016\/bs.mcb.2024.05.013_bb0255","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.mcb.2024.05.013_bb0260","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.mcb.2024.05.013_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12976-016-0032-7","article-title":"A mathematical model of tumor growth and its response to single irradiation","volume":"13","author":"Watanabe","year":"2016","journal-title":"Theoretical Biology and Medical Modelling"},{"issue":"23","key":"10.1016\/bs.mcb.2024.05.013_bb0270","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.3390\/jcm11236963","article-title":"HER2 expression in peritoneal dissemination of high-grade serous ovarian carcinoma: A comparative study of immunohistochemical reactivity using four HER2 antibodies","volume":"11","author":"Yeo","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"12","key":"10.1016\/bs.mcb.2024.05.013_bb0275","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2967\/jnumed.110.086819","article-title":"Antitumor effects of a human dimeric antibody fragment 131 I-AFRA-DFM5.3 in a mouse model for ovarian cancer","volume":"52","author":"Zacchetti","year":"2011","journal-title":"Journal of Nuclear Medicine"}],"container-title":["Methods in Cell Biology","Animal Models of Disease - Part C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24001559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X24001559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:49:05Z","timestamp":1762231745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X24001559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443222429"],"references-count":54,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2024.05.013","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}